CU, N., J, D., K, N., C, d. C., S, K., L, E., . . . MD, L. (2025). Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: Phase 2 VISION/HO141 trial. Blood advances, 9(15), 3665. https://doi.org/10.1182/bloodadvances.2024015180
Chicago Style (17th ed.) CitationCU, Niemann, et al. "Long-term Follow-up of MRD-guided Ibrutinib Plus Venetoclax in Relapsed CLL: Phase 2 VISION/HO141 Trial." Blood Advances 9, no. 15 (2025): 3665. https://doi.org/10.1182/bloodadvances.2024015180.
MLA (9th ed.) CitationCU, Niemann, et al. "Long-term Follow-up of MRD-guided Ibrutinib Plus Venetoclax in Relapsed CLL: Phase 2 VISION/HO141 Trial." Blood Advances, vol. 9, no. 15, 2025, p. 3665, https://doi.org/10.1182/bloodadvances.2024015180.
Warning: These citations may not always be 100% accurate.
